AND017 clinical trials
How each study uses AND017 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the AND017 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2025 (3); 2 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Kind Pharmaceuticals LLC (10)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test AND017, phase 3 first.
- Dec 2026A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)Phase 3 · Kind Pharmaceuticals LLC
- Dec 2026A Study of Safety and Efficiency of AND017 in Patients With β-thalassemiaPhase 2 · Kind Pharmaceuticals LLC
- Dec 2026A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic SyndromePhase 2 · Kind Pharmaceuticals LLC
Studies
Open first, then newest update. How each study uses AND017 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study of AND017 in Cancer Related Anemic Patients Receiving ChemotherapyNot yet recruitingPhase 2Kind Pharmaceuticals LLCNCT06075030Written as AND017
- A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving ChemotherapyNot yet recruitingPhase 2Kind Pharmaceuticals LLCNCT06075043Written as AND017
- A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With AnemiaRecruitingPhase 3Kind Pharmaceuticals LLCNCT07494409Written as AND017 capsules
- A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)RecruitingPhase 3Kind Pharmaceuticals LLCNCT07487727Written as AND017
- A Study of Safety and Efficiency of AND017 in Patients With β-thalassemiaRecruitingPhase 2Kind Pharmaceuticals LLCNCT06302491Written as AND017 capsules
- A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic SyndromeRecruitingPhase 2Kind Pharmaceuticals LLCNCT06304103Written as AND017
- A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on DialysisCompletedPhase 2Kind Pharmaceuticals LLCNCT05265325Written as AND017 capsules TIW
- A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) PatientsCompletedPhase 2Kind Pharmaceuticals LLCNCT05035641Written as AND017
- A Dose-escalation Study of AND017 in Healthy SubjectsCompletedPhase 1Kind Pharmaceuticals LLCNCT04751539Written as AND017 single dose
- A Food-Effect Study of AND017 in Healthy ParticipantsCompletedPhase 1Kind Pharmaceuticals LLCNCT04712500Written as AND017